StreetAlpha.app
Home › Stocks › CCCC

C4 Therapeutics, Inc. (CCCC)

Healthcare
$2.48
▲ +1.64%
LAST CLOSE · NOV 20

C4 Therapeutics develops drugs that remove disease-causing proteins from cells, with candidates in cancer and inflammation. It last closed at $2.48 on Nov 20, up 1.64% on the day. The next earnings report for CCCC is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, CCCC reported EPS of -$0.16 on revenue of $8.5M, with revenue down 24.6% from a year ago. Over its last 8 reports the stock moved an average of 6.6% the session after earnings. Over the last 12 months CCCC insiders bought $0 of stock on the open market and sold $145K, according to SEC Form 4 filings.

AI Auto Pilots
Is CCCC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CCCC.

Key Stats

Last 12 months
Results
Revenue
$32.3M
+7.2% vs a year ago
Net income
−$91.1M
−282.2% margin
EPS (diluted)
−$0.63
Free cash flow
−$79.7M
−247.1% margin
Valuation
Market cap
$325.7M
131.3M shares
P/E
–
No P/E while losing money
Price to sales
10.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$32.4M
At Sep 30
Shareholder equity
$228.2M
Buybacks
$253K
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $45.8M$45.8MFY2021FY2022: $31.1M$31.1MFY2022FY2023: $20.8M$20.8MFY2023FY2024: $35.6M$35.6MFY2024FY2025: $35.9M$35.9MFY2025

From CCCC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
-$0.16
Quarter ended Sep 2026
Year ago EPS
-$0.44
Same quarter last year
Revenue
$8.5M
−24.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.49Dec '24Mar 2025: -$0.37Mar '25Jun 2025: -$0.37Jun '25Sep 2025: -$0.44Sep '25Dec 2025: -$0.09Dec '25Mar 2026: -$0.20Mar '26Jun 2026: -$0.18Jun '26Sep 2026: -$0.16Sep '26Latest -$0.16
Revenue by quarter
Dec 2024: $5.2MDec '24Mar 2025: $7.2MMar '25Jun 2025: $6.5MJun '25Sep 2025: $11.2MSep '25Dec 2025: $11.0MDec '25Mar 2026: $6.2MMar '26Jun 2026: $6.6MJun '26Sep 2026: $8.5MSep '26Latest $8.5M
How CCCC moved after its last 8 reports
Average move the session after a report ±6.6%
Nov 5, 2026Time not announced−5.5%
Aug 11, 2026Time not announced+6.9%
May 12, 2026Time not announced0.0%
Feb 26, 2026Time not announced+0.4%
Nov 6, 2025Time not announced+0.4%
Aug 7, 2025Time not announced+31.6%
May 7, 2025Time not announced+6.4%
Feb 27, 2025Time not announced−1.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CCCCStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CCCC
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CCCC

Technical Analysis

CCCC · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 19% below its 20 day and 22% below its 50 day average. It is 32% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot at $2.45, and the nearest resistance the Pivot R1 at $2.58.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 8.9%/day
Key levels
$5.1752 week high+108.5%
$3.44100 day average+38.7%
$3.27200 day average+31.9%
$3.25Swing high (Oct 22)+31.0%
$3.0350 day average+22.2%
$2.9520 day average+19.0%
$2.58Pivot R1+4.0%
$2.48Last close
$2.45Pivot−1.2%
$2.35Pivot S1−5.2%
$1.6952 week low−31.9%
Indicators
RSI (14)33.43Weak, oversold below 30Neutral
MACD-0.17Below its signal lineBearish
Stochastic9.8Near the bottom of its rangeOversold
ADX (14)24.7Weak trend
Williams %R-85.5Oversold below −80, overbought above −20Oversold
CCI (20)-132.4Oversold below −100, overbought above 100Oversold
Rate of change−20.0%Change over 10 sessionsBearish
ATR (14)$0.22Typical daily range, 8.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CCCC

What happened before

See how CCCC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CCCC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CCCC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CCCCHow many large options trades hit CCCC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

CCCC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲97 buying vs 54 selling
  • ▲Held by funds +15.3 pts
  • ▲Funds holding +2
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding153151+1.3%
In funds' top 10220.0%
Held by funds105.0%89.6%+15.3 pts
New / increased25 / 7253 / 53−8.5%
Reduced / sold out28 / 2630 / 27−5.3%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CCCC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CCCC Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$145K2 sales · 2 insiders
85% of the selling was under pre-arranged trading plans.
2026-01 sold $22K2026-11 sold $122KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 12Kendra AdamsCFOSale plan45,173$2.71$122K
Jan 16Leonard ReynoChief Medical OfficerSale10,000$2.22$22K
Feb 18, 2025Scott N BoyleChief Business OfficerSale plan1,159$3.15$4K
Every insider buy and sale for CCCC over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CCCC insider trades →

From SEC Form 4 filings by CCCC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CCCC is in one of them and how their past CCCC trades turned out.

CCCC in the AI portfolios
Loading…

CCCC News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CCCC in an article yet. Here's the latest on the wider market.

CCCC in the news

About C4 Therapeutics

C4 Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts. It develops medicines based on targeted protein degradation, a process that removes disease-causing proteins from cells. Its most advanced drug candidates are being tested in cancers, including multiple myeloma and lung cancer, and it is also building programs for inflammation and neurological diseases. The company works with partners such as Merck KGaA, Roche and Pfizer on drug discovery and development.

Headquarters
Watertown, MA
Founded
2015